Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals new insights into canine mammary cancer
The study found that spaying can increase the risk of more aggressive cancers.

Higher serum oestrogen levels linked to improved survival times

US researchers have shed new light on the complex role of oestrogen in the development of canine mammary tumours.


The study, published in PLOS ONE, found that while spaying at a young age can reduce a dog’s risk of developing mammary cancer, it can increase the risk of more aggressive cancers.

Furthermore, the study found that in spayed animals with mammary tumours, higher serum oestrogen levels were protective, associated with longer times to metastasis and improved survival times.


Senior author and veterinary oncologist Karin U Sorenmo from the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet), said: “Dogs that remain intact and have their ovaries develop many more mammary tumors than dogs that were spayed, so removing that source of estrogen does have a protective effect. 


“Estrogen does seem to drive mammary cancer development. But what it does for progression to metastasis—that I think is more complicated.”

In the study, researchers assessed 159 dogs with mammary cancer, 130 of which were spayed as part of the study and 29 that remain intact. Besides surgically removing the dogs’ measurable tumours, the team collected information on serum oestrogen levels, tumour types, disease grade and stage, time to metastasis, and survival time. 


They found that, despite oestrogen’s link with an increased risk of developing mammary tumours, higher serum oestrogen levels appeared to help dogs avoid some of the riskiest aspects of their disease.

Interestingly, when dogs were spayed at the same time as having their tumours removed, those with oestrogen-receptor positive tumours that had higher serum oestrogen took longer to develop metastatic disease and survived longer than dogs with lower oestrogen levels - confirming that such tumours depend on oestrogen for progression.

The researchers also found that the protective role of oestrogen was also pronounced in dogs with oestrogen-receptor negative mammary tumours. In these higher-risk cancers, high serum oestrogen was associated with delayed or absent metastasis.

Furthermore, the study showed that dogs with low oestrogen are at a far higher risk for developing other non-mammary aggressive fatal tumours after mammary tumour surgery.

Sorenmo and her colleagues have been studying mammary tumours in dogs as a way to improve care and treatment for pets, but to also reveal insights into human breast cancer. 


Their research used data from the Penn Vet Shelter Canine Mammary Tumour Program, through which shelter dogs with mammary tumours receive treatment, are studied by researchers like Sorenmo, and found foster or permanent homes.

Image (C) Penn State University.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.